Show simple item record

dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorDeldar Abad Paskeh, Mahshid
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2022-03-25T10:03:57Z
dc.date.available2022-03-25T10:03:57Z
dc.date.issued2022en_US
dc.identifier.citationAshrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022 Mar 22;41(1):105.en_US
dc.identifier.urihttps://doi.org/10.1186/s13046-022-02293-6
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2588
dc.description.abstractProstate cancer is a leading cause of death worldwide and new estimates revealed prostate cancer as the leading cause of death in men in 2021. Therefore, new strategies are pertinent in the treatment of this malignant disease. Macroautophagy/autophagy is a "self-degradation" mechanism capable of facilitating the turnover of long-lived and toxic macromolecules and organelles. Recently, attention has been drawn towards the role of autophagy in cancer and how its modulation provides effective cancer therapy. In the present review, we provide a mechanistic discussion of autophagy in prostate cancer. Autophagy can promote/inhibit proliferation and survival of prostate cancer cells. Besides, metastasis of prostate cancer cells is affected (via induction and inhibition) by autophagy. Autophagy can affect the response of prostate cancer cells to therapy such as chemotherapy and radiotherapy, given the close association between autophagy and apoptosis. Increasing evidence has demonstrated that upstream mediators such as AMPK, non-coding RNAs, KLF5, MTOR and others regulate autophagy in prostate cancer. Anti-tumor compounds, for instance phytochemicals, dually inhibit or induce autophagy in prostate cancer therapy. For improving prostate cancer therapy, nanotherapeutics such as chitosan nanoparticles have been developed. With respect to the context-dependent role of autophagy in prostate cancer, genetic tools such as siRNA and CRISPR-Cas9 can be utilized for targeting autophagic genes. Finally, these findings can be translated into preclinical and clinical studies to improve survival and prognosis of prostate cancer patients.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1186/s13046-022-02293-6en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-tumor Compoundsen_US
dc.subjectAutophagyen_US
dc.subjectBiomarkeren_US
dc.subjectNon-coding RNAsen_US
dc.subjectProstate Canceren_US
dc.subjectTherapy Response.en_US
dc.titleTargeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic responseen_US
dc.typereviewen_US
dc.contributor.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.contributor.authorID0000-0003-0391-1769en_US
dc.contributor.institutionauthorZarrabi, Ali
dc.identifier.volume41en_US
dc.identifier.issue1en_US
dc.identifier.startpage105en_US
dc.relation.journalExp Clin Cancer Resen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.description.pubmedpublicationid35317831en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record